The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials.
o Lesson learnt – the evolution of response criteria in immunotherapy
o Overview of immune modified response criteria
o Challenging cases – pitfall of imaging interpretation
• Dr. Yan Liu, CMO, Median Technologies
• Dr. Antoine Iannessi, Medical Director iCRO, Median Technologies